AR038311A1 - Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes - Google Patents
Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantesInfo
- Publication number
- AR038311A1 AR038311A1 ARP030100201A ARP030100201A AR038311A1 AR 038311 A1 AR038311 A1 AR 038311A1 AR P030100201 A ARP030100201 A AR P030100201A AR P030100201 A ARP030100201 A AR P030100201A AR 038311 A1 AR038311 A1 AR 038311A1
- Authority
- AR
- Argentina
- Prior art keywords
- surface antigen
- formulations
- hepatitis
- antigens
- virus
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 10
- 102000036639 antigens Human genes 0.000 title abstract 10
- 108091007433 antigens Proteins 0.000 title abstract 10
- 239000000203 mixture Substances 0.000 title abstract 6
- 241000700721 Hepatitis B virus Species 0.000 title abstract 2
- 230000000091 immunopotentiator Effects 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 5
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 230000002434 immunopotentiative effect Effects 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 229940021747 therapeutic vaccine Drugs 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Antígeno de superficie por vía mucosal con el objetivo de favorecer un incremento en la respuesta inmune contra los antígenos coadministrados en las formulaciones que se describen. Las formulaciones se obtienen a partir del doble uso del antígeno de superficie como agente inmunopotenciador y al mismo tiempo como antígeno vacunal. Formulaciones múltiples del antígeno de superficie de la Hepatitis B y antígenos heterólogos, con niveles de inmunogenicidad similares a los obtenidos luego de administración parenteral y con una economía de componentes capaz de dispensar el uso de adyuvantes nasales, convirtiendo a los mismos antígenos en elementos capaces de favorecer el incremento de la respuesta a los antígenos coadministrados. Uso del antígeno de superficie del Virus de la Hepatitis B y las formulaciones antigénicas resultantes son aplicables en la industria farmacéutica como formulaciones vacunales preventivas o terapéuticas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20020019A CU23031A1 (es) | 2002-01-24 | 2002-01-24 | Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038311A1 true AR038311A1 (es) | 2005-01-12 |
Family
ID=27587819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100201A AR038311A1 (es) | 2002-01-24 | 2003-01-23 | Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050025780A1 (es) |
| EP (1) | EP1493447A2 (es) |
| KR (1) | KR20040081469A (es) |
| CN (1) | CN1703241A (es) |
| AR (1) | AR038311A1 (es) |
| BR (1) | BR0307121A (es) |
| CA (1) | CA2471727A1 (es) |
| CU (1) | CU23031A1 (es) |
| MY (1) | MY141983A (es) |
| WO (1) | WO2003061692A2 (es) |
| ZA (1) | ZA200405140B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23405A1 (es) * | 2003-10-20 | 2009-08-04 | Ct Ingenieria Genetica Biotech | Composiciones farmacéuticas para uso terapéutico |
| GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
| PE20070163A1 (es) | 2005-06-27 | 2007-03-01 | Glaxosmithkline Biolog Sa | Composicion inmunogenica de conjugados de sacaridos de n. meningitidis |
| CN104958759B (zh) * | 2015-06-24 | 2018-04-27 | 康希诺生物股份公司 | 多价脑膜炎球菌制剂盒、疫苗制剂及其制备方法 |
| KR102692762B1 (ko) | 2016-09-02 | 2024-08-08 | 사노피 파스퇴르 인크 | 네이세리아 메닌기티디스 백신 |
| WO2019032046A1 (en) * | 2017-08-10 | 2019-02-14 | Yisheng Biopharma (Singapore) Pte Ltd | COMPOSITION FOR TREATING AND / OR PREVENTING HEPATITIS B VIRUS INFECTION AND USE THEREOF |
| JP7588955B2 (ja) * | 2017-10-05 | 2024-11-25 | 東興薬品工業株式会社 | 経鼻ｂ型肝炎ワクチン組成物およびその製造方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4547368A (en) * | 1983-12-20 | 1985-10-15 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Hepatitis B core antigen vaccine made by recombinant DNA |
| ATE444079T1 (de) * | 1992-05-23 | 2009-10-15 | Glaxosmithkline Biolog Sa | Kombinierte impfstoffe, die hepatitis b oberfläche antigen und andere antigenen enthalten |
| US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
| GB9503863D0 (en) * | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
| CU22629A1 (es) * | 1997-03-06 | 2000-12-22 | Ct Ingenieria Genetica Biotech | Formulaciones inmunopotenciadoras para uso vacunal |
| CU22871A1 (es) * | 1998-12-02 | 2003-10-21 | Ct Ingenieria Genetica Biotech | Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal |
-
2002
- 2002-01-24 CU CU20020019A patent/CU23031A1/es unknown
-
2003
- 2003-01-22 CN CNA038026260A patent/CN1703241A/zh active Pending
- 2003-01-22 US US10/501,570 patent/US20050025780A1/en not_active Abandoned
- 2003-01-22 EP EP03731653A patent/EP1493447A2/en not_active Withdrawn
- 2003-01-22 BR BRPI0307121-9A patent/BR0307121A/pt not_active IP Right Cessation
- 2003-01-22 WO PCT/CU2003/000001 patent/WO2003061692A2/es not_active Ceased
- 2003-01-22 KR KR10-2004-7011504A patent/KR20040081469A/ko not_active Ceased
- 2003-01-22 CA CA002471727A patent/CA2471727A1/en not_active Abandoned
- 2003-01-23 AR ARP030100201A patent/AR038311A1/es not_active Application Discontinuation
- 2003-01-24 MY MYPI20030252A patent/MY141983A/en unknown
-
2004
- 2004-06-28 ZA ZA200405140A patent/ZA200405140B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CU23031A1 (es) | 2005-02-23 |
| WO2003061692A3 (es) | 2004-10-21 |
| CN1703241A (zh) | 2005-11-30 |
| EP1493447A2 (en) | 2005-01-05 |
| CA2471727A1 (en) | 2003-07-31 |
| BR0307121A (pt) | 2006-04-11 |
| KR20040081469A (ko) | 2004-09-21 |
| US20050025780A1 (en) | 2005-02-03 |
| WO2003061692A2 (es) | 2003-07-31 |
| MY141983A (en) | 2010-08-16 |
| ZA200405140B (en) | 2006-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041880A1 (es) | Composicion inmunogena | |
| Lee et al. | Recent advances of vaccine adjuvants for infectious diseases | |
| WO2001091536A3 (en) | Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens | |
| AR052625A1 (es) | Nueva composicion | |
| AR032597A1 (es) | Uso de antigenos del virus de la gripe inactivado, en la preparacion de vacunas de una sola dosis intranasal; metodo para la profilaxis de enfermedades o de infecciones gripales en pacientes; equipos que comprenden dichas vacunas en dosis unicas y metodo para fabricar vacunas para la gripe para apli | |
| ATE499113T1 (de) | Influenzavirus-impfstoffzusammensetzung | |
| MX9702336A (es) | Composiciones de vacuna. | |
| ZA202401922B (en) | Coronavirus vaccine formulations | |
| CY1115308T1 (el) | Συνθεσεις εμβολιου οι οποιες περιεχουν ανοσοενισχυτικο εκδοχο σαπωνινης | |
| PT1361890E (pt) | Formulações vacinais de influenza para distribuição intradérmica | |
| AR046840A1 (es) | Polisacaridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes | |
| HRP20210608T1 (hr) | Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije | |
| AR061894A1 (es) | Vacunas para malaria | |
| BR112023019301A2 (pt) | Formulações de vacina de coronavírus | |
| UY26882A1 (es) | Nuevo tratamiento | |
| MX2024006589A (es) | Formulaciones de vacunas contra el coronavirus. | |
| AR038311A1 (es) | Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes | |
| MX9205336A (es) | Vacuna contra el agente de la anemia del pollo. | |
| AR065765A1 (es) | Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias | |
| Silveira et al. | Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice | |
| TW200617166A (en) | Multivalent avian influenza vaccines | |
| BRPI0414073A (pt) | método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo | |
| UY27621A1 (es) | " antígeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes" | |
| AR054259A1 (es) | Vacuna contra virus de papiloma humano (hpv) | |
| ECSP14023407A (es) | Virus de la enfermedad de marek modificado y vacunas elaboradas con él |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |